Smartphone Enabled Hearing Study

Recruitment & Eligibility

Inclusion Criteria

Age ≥ 18 years
Proficient in written and spoken English, defined by self-report
Mild- to moderate- hearing loss as measured by pure tone audiometry (PTA) reference test, or self-report of perceived hearing loss and 15-25 dB HL (by 4PTA)
Participants have access to stable internet connection

Exclusion Criteria

Ear anatomy non-conducive to comfortable wear of headphone
Active ear disease
Cerumen impaction that cannot be removed
Sudden loss of hearing (in the preceding 90 days), defined by self-report
Self Report of loud environmental sound exposure (e.g., concert; construction site; fireworks) without hearing protection within 72 hours of reference PTA assessed at Clinic Visit 1
Tinnitus that impacts one's daily life, defined by self-report
Use of cochlear implants
Self-reported issues with small or confined spaces such as a single-person enclosed booth, and/or claustrophobia
Health technology, fitness, media outlet employees (or spouse of employees), or employees of CRO/sites contracted to execute this study
User noted preference to not wear headphone consistently, or charge headphone and smartphone consistently, during field-use
Hearing loss >60 dB HL at 0.25-3kHz and >65 dB HL at 4kHz in either ear; assessed during PTA
Hearing loss that requires electroacoustic settings which are not acoustically stable in the participant's ear per audiologist judgement
Current regular use of hearing aids
Active treatment, or treatment in the past 6 months, with either a chemotherapeutic drug for cancer, or radiation therapy to the head or neck region
Active treatment, or treatment in the past 6 months, with parenteral aminoglycoside antibiotics
In the Investigator's opinion, unable to adhere to study procedures

Primary Outcome Measures

Name	Time	Method
International Outcome Inventory for Hearing Aids (IOI-HA) Survey Results	Approximately 18-31 days upon enrollment	The IOI-HA survey is a 7-item questionnaire that assesses the effectiveness of hearing aids. It was self-administered to each study participant one time at the third scheduled clinic visit approximately 18-31 days after enrollment. For each participant, the IOI-HA total score (which ranges from 7-35 where higher scores indicate a better outcome) was computed and the mean IOI-HA scores were compared between the Experimental and Reference Groups.

Secondary Outcome Measures